Fennec (FENC) Q2 2026 earnings review
Commercial Expansion Pays Off as Fennec Turns Firmly Profitable
Fennec delivered a breakout quarter, achieving $17.1M in net product sales (+78% YoY) and definitively turning the corner to profitability with $1.97M in Net Income. The numbers validate management's 'Project Ignite' strategy—a significant Q1 investment to expand the sales force targeting the much larger Adolescent and Young Adult (AYA) market. Importantly, Fennec defied its own cautious Q1 guidance which predicted a Q2 cash dip; instead, cash grew to $41.2M. The company is now proving immense operating leverage as it shifts from a pediatric niche to a broader standard of care.
🐂 Bull Case
The first full quarter of the expanded sales force yielded an acceleration in demand. Record PEDMARK demand is carrying into Q3, proving the AYA market is highly receptive to the drug.
Management warned in Q1 of a potential Q2 cash dip due to collection cycles. Instead, cash grew from $40.1M to $41.2M. Operations are now entirely self-funding.
🐻 Bear Case
S&M expenses more than doubled YoY to $10.7M (up from $4.8M). The company must maintain steep revenue growth to justify this higher fixed-cost baseline.
Off-label AYA adoption relies heavily on ongoing Investigator-Sponsored Studies (ISTs) rather than formal FDA label expansion, carrying inherent clinical and regulatory risks if any adverse data emerges.
⚖️ Verdict: 🟢
Bullish. The commercial strategy is executing flawlessly. Scaling revenue by 78% while flipping Net Income from a $3M loss to a $2M profit demonstrates the immense operating leverage of this model.
Key Themes
Project Ignite Delivers Immediate ROI
The Q1 decision to dramatically expand the sales force (increasing target prescribers from 1,300 to >5,000) yielded immediate dividends. Net product sales accelerated to $17.1M, representing a 14% sequential jump and a 78% YoY increase. This validates the scalability of Fennec's commercial platform into the AYA demographic.
Real-World Evidence Strengthening Off-Label Use
Four independent studies were presented at ASCO 2026, reinforcing that PEDMARK safely integrates into patient care without compromising cisplatin's antitumor activity. Because PEDMARK is only formally approved for pediatric use, these Investigator-Sponsored Studies (ISTs) are the critical mechanism driving adoption in the adult/AYA market.
S&M Expense Doubling Requires Sustained Growth
Selling and Marketing expenses hit $10.7M (up from $4.8M in 25Q2). Management notes this includes both commercialization costs and a reallocation of select G&A expenses. While G&A dropped to $4.6M (down from $6.5M) due to concluding litigation, the heavy skew toward commercial spend means Fennec must maintain high double-digit revenue growth to prevent margin compression.
Operating Leverage is Now Visible
Fennec is demonstrating textbook pharma operating leverage. Gross margins remain near 96%. With R&D effectively zero ($118K in 26Q2) and G&A declining post-litigation, nearly every incremental gross profit dollar beyond the new S&M baseline drops straight to the bottom line, resulting in $2.8M in Adjusted EBITDA.
Other KPIs
Reversing. Flipped from a loss of $1.2M in 25Q2 to a solid $2.8M profit in 26Q2. This isolates cash operating performance by stripping out $1.77M in share-based compensation and a $710K non-cash revenue recognition item related to the Norgine partnership.
Accelerating. Cash increased by $1.1M sequentially from $40.1M in Q1. This explicitly contradicts the CFO's conservative Q1 guidance, which warned that Q2 cash would likely dip due to working capital and collection cycles. The upside surprise cements the company's self-sustaining financial profile.
Guidance
Stable. The company continues to provide no formal numeric revenue or EPS guidance. They simply reiterated that the $41.2M cash position, combined with projected PEDMARK revenues, is sufficient to fund the business based on the current operating plan.
Key Questions
S&M Baseline
Selling and marketing expenses reached $10.7M this quarter. Is this the new steady-state run rate for the expanded commercial organization, or were there one-time ASCO/launch costs embedded in this figure?
Norgine Milestone Timing
You recognized $710K in non-cash material rights revenue this quarter related to Norgine. What is the latest visibility on actual cash milestones or material royalties from the European rollout in H2 2026?
Label Expansion Strategy
Given the successful presentation of real-world evidence at ASCO for AYA and adult populations, what is the specific timeline and mechanism (e.g., sNDA) for seeking formal FDA label expansion beyond the pediatric indication?